Cytokines as targets for anti-inflammatory agents

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 88-96

  Moreland, Larry W ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Anti inflammatory agents; Biologics; Cytokines; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CD20 ANTIGEN; CERTOLIZUMAB PEGOL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 6; JANUS KINASE INHIBITOR; LENERCEPT; LYMPHOTOXIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE SYK INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

APOPTOSIS; B LYMPHOCYTE; BACTERIAL INFECTION; CANCER RISK; CELL MEDIATED CYTOTOXICITY; CONFERENCE PAPER; COUGHING; CYTOLYSIS; DISEASE ACTIVITY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; HEART FAILURE; HUMAN; HYPOTENSION; IMMUNOGENICITY; INFECTION RISK; LEUKOCYTE; LIPID BLOOD LEVEL; NONHODGKIN LYMPHOMA; PREVALENCE; PRURITUS; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 73849084973     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05072.x     Document Type: Conference Paper

References (75)

1. Boers, M., A.C. Verhoeven, H.M. Markusse, et al. 1997. Randomized comparison of combined step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 350: 309-318.
2. Mottonen, T., P. Hannonen, M. Leirisalo-Repo, et al. 1999. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 353: 1568-1573. (Pubitemid 29219206)
3. O'Dell, J.R., C.E. Haire, N. Erikson, et al. 1996. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334: 1287-1291.
4. Landewe, R.B.M., M. Boers, A.C. Verhoeven, et al. 2002. COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 46: 347-356.
5. Mottonen, T., P. Hannonen, M. Korpela, et al. ; FINRACoTrialGroup. 2002. Delay to institution of therapy and induction of remission using single-drug or combination-disease modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 46: 894-898.
6. Smolen, J.S., J.R. Kalden & D.L. Scott, et al. 1999. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. European Leflunomide Study Group Lancet 353: 259-266.
7. Cohen, S., M. Schiff, A. Weaver, et al. 1999. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch. Intern. Med. 159: 2542-2550.
8. Bathon, J.M., R.W. Martin, R.M. Fleischmann, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343: 1586-1593.
9. Moreland, L.W., M.H. Schiff, S.W. Baumgartner, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130: 478-486.
10. Weinblatt, M.E., J.M. Kremer, A.D. Bankhurst, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340: 253-259.
11. Moreland, L.W., S.W. Baumgartner, M.H. Schiff, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337: 141-147.
12. Elliott, M.J., R.N. Maini, M. Feldmann, et al. 1994. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
13. Elliott, M.J., R.N. Maini, M. Feldmann, et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factoralpha. Arthritis Rheum. 36: 1681-1690.
14. Maini, R., E.W. St Clair, F. Breedveld, et al. 1999. Infliximab (chimeric anti-tumour necrosis factor-á monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354: 1932-1939.
15. Lipsky, P.E., D.M. Van Der Heijde, E.W. St Clair, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343: 1594-1602.
16. Weinblatt, M., E. Keystone, D. Furst, et al. 2003. Adalimumab, a fully human anti-TNF-á monoclonal antibody, for the treatment of rheumatoid arthritis patients taking concomitant methotrexate: the ARMADA Trial. Arthritis Rheum. 48: 35-45.
17. Bresnihan, B., J.M. Alvaro-Gracia, M. Cobby, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41: 2196-2204.
18. Jiang, Y., H.K. Genant, I. Watt, et al. 2000. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43: 1001-1009.
19. Choi, H.K., M.A. Hernan, J.D. Seeger, et al. 2002. Methotrexate andmortality in patients with rheumatoid arthritis: a prospective study. Lancet 359: 1173-1177.
20. Lee, D.M. & M.E. Weinblatt. 2001. Rheumatoid arthritis. Lancet 358: 903-911.
21. Van Der Heide, A., J.W.G. Jacobs & J.W.J. Bijlsma. 1996. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann. Intern. Med. 124: 699-707.
22. Lard, L.R., M. Boers, A.Verhoeven, et al. 2002. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA Class II antigens with progression of joint damage. Arthritis Rheum. 46: 899-905. (Pubitemid 34303800)
23. Boers, M. 2001. Rheumatoid arthritis. Treatment of early disease. Rheum. Dis. Clin. N. Am. 27: 405-414.
24. Moreland, L.W. & S.L. Bridges Jr. 2001. Early rheumatoid arthritis: a medical emergency? Am. J. Med. 111: 498-500.
25. Boers, M. 2003. Add-on or step-up trials for new drug development in rheumatoid arthritis: A new standard? Arthritis Rheum. 48: 1481-1483.
26. Breedveld, F.C., M.H. Weisman, A.F. Kavanaugh, et al. 2006. The PREMIER Study: A multicenter, Moreland: Targeted Cytokines as Anti-inflammatory Agents 95 randomized, double-blind clinical trial of combination therapywith adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54: 26-37.
27. de Vries-Bouwstra, J.K., B. Dijkmans & F. Breedveld. 2005. Biologics in early rheumatoid arthritis. Rheum. Dis. Clin. N. Am. 31: 745-762.
28. Edwards, J., L. Szczepanski, J. Szechinski, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581. (Pubitemid 38758544)
29. Emery, P. 2006. Clinical review: Treatment of rheumatoid arthritis. BMJ 332: 152-155.
30. Emery, P., R. Fleischmann, A. Filipowicz- Sosnowska, et al. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. 54: 1390-1400.
31. Emery, P. 2005. Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis. Drugs Today 41: 155-163.
32. Genovese, M.C., J. Becker, M. Schiff, et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor á inhibition.N. Engl. J. Med. 353: 1114-1123.
33. Goekoop-Ruiterman, Y.P.M., J.K. de Vries- Bouwstra, C.F. Allaart, et al. 2005. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST Study). Arthritis Rheum. 52: 3381-3390.
34. Hyrich, K.L., D. Symmons, K.D. Watson & A.J. Silman. 2006. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis. Arthritis Rheum. 54: 1786-1794.
35. Keystone, E.C., A.F. Kavanaugh, J.T. Sharp, et al. 2004. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52- week trial. Arthritis Rheum. 50: 1400-1411.
36. Klareskog, L., D. Van Der Heijde, J.P. de Jager, et al. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681.
37. Kremer, J.M., R. Westhovens, M. Leon, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New Engl. J. Med. 349: 1907-1915.
38. Moreland, L.W., R. Alten, F. Van de Bosch, et al. 2002. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double blind, placebo-controlled clinical trial evaluating CTLA- 4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46: 1470-1479.
39. Quinn, M.A. & P. Emery. 2005. Potential for altering rheumatoid arthritis outcome. Rheum. Dis. Clin. N. Am. 31: 763-772.
40. Quinn, M.A., P.G. Gonaghan, P.J. O'Connor, et al. 2005. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 52: 27-35.
41. Smolen, J.S., C. Han, M. Bala, et al. 2005. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement. Arthritis Rheum. 52: 1020-1030.
42. Smolen, J.S., D. Van Der Heijde, E.W. St Clair, et al. 2006. Predictors of joint damage in patients with early rheumatoid arthritis treated with highdose methotrexate with or without concomitant infliximab. Arthritis Rheum. 54: 702-710.
43. St Clair, E.W., D. Van Der Heijde, J.S. Smolen, et al. 2004. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 50: 3432-3443.
44. Van Der Heijde, D., L. Klareskog, V. Rodriguez-Valverde, et al. 2006. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from TEMPO Study, a double blind, randomized trial. Arthritis Rheum. 54: 1063-1074.
45. Weyand, C.M. & J. Goronzy. 2006. T-cell-targeted therapies in rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2: 201-210.
46. Lard, L.R., H. Visser, I. Speyer, et al. 2001. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 111: 446-451.
47. Yelin, E.H. & P.P. Katz. 2002. Focusing interventions for disability among patients with rheumatoid arthritis. Arthritis Rheum. 47: 231-233.
48. Escalante, A.&I. del Rincon. 2002.The disablement process in rheumatoid arthritis. Arthritis Rheum. 47: 333-342.
49. van Doornum, S., G. McColl & I.P. Wicks. 2002. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46: 862-873.
50. Wong, J.B., D.R. Ramey & G. Singh. 2001. Longterm morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum. 44: 2746-2749.
51. Bacon, P.A.&J.N.Townend. 2001. Nails in the coffin: Increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum. 44: 2707-2710.
52. del Rincon, I., K. Williams, M.P. Stern, et al. 2001. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44: 2737-2745.
53. Kobelt, G., P. Lindgren, A. Singh & L. Klareskog. 2005. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64: 1174-1179.
54. Genovese, M.C. 2009. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60: 317-320.
55. Cohen, S.B., T.-T. Cheng, V. Chindalore, et al. 2009. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60: 335-344.
56. Weinblatt, M.E., A. Kavanaugh, R. Burgos-Vargas, et al. 2008. Treatment of rheumatoid arthritis with a Syk kinase inhibitor. Arthritis Rheum. 58: 3309-3318.
57. Smolen, J.S., A. Beaulieu, A. Rubbert-Roth et al. : OPTION Investigators. 2008. Effect of interleukin- 6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTIONstudy): a doubleblind, placebo-controlled, randomized trial. Lancet 371: 987-997.
58. Keystone, E.C., M.C. Genovese, L. Klareskog et al. 2008. Golimumab, a human antibody to TNF-á given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: the GOFORWARD Study. ARD Online, December.
59. Bender, N.K., C.E. Heilig, B. Droll, et al. 2007. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int. 27: 269-274.
60. Fefferman, D.S. & R.J. Farrell. 2005. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm. Bowel Dis. 11: 497-503.
61. Anderson, P.J. 2005.Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin. Arthritis Rheum. 34: 19-22.
62. Anderson, P., J. Louie, A. Lau & M. Broder. 2005. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr. Rheumatol. Rep. 7: 3-9.
63. Baert, F., M. Noman, S. Vermeire, et al. 2009. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348: 601-608.
64. Aarden, L., S.R. Ruuls & G. Wolbink. 2008. Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibodymeasurement. Curr. Opin. Immunol. 20: 431-435.
65. Wolbink, G.J.,M. Vis,W. Lems, et al. 2006. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54: 711-715.
66. Saag, K.G.,G.G. Ten,N.M. Patkar, et al. 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 56: 762-784.
67. Danila, M.I., N.M. Patkar, J.R. Curtis, et al. 2008. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr. Opin. Rheumatol. 20: 327-333.
68. Patkar, N.M., G.G. Teng, J.R. Curtis & K.G. Saag. 2008. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr. Opin. Rheumatol. 20: 320-326.
69. Curtis, J.R., J. Xi,N. Patkar, et al. 2007. Drug-specific and time-dependent risk of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 56: 4226-4227. (Pubitemid 350262351)
70. Love, T. & D.H. Solomon. 2008. The relationship between cancer and rheumatoid arthritis: still a large research agenda. Arthritis Rheum. 10: 109.
71. Setoguchi, S., S. Schneeweiss, J. Avorn, et al. 2008. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am. Heart J. 156: 336-341.
72. Schneeweiss, S., S. Setoguchi, M.E. Weinblatt, et al. 2007. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 56: 1754-1764.
73. Emery, P., F.C. Breedveld, S. Hall, et al. 2008. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 372: 375-382.
74. Goekoop-Ruiterman, Y.P., J.K. de Vries-Bouwstra, C.F. Allaart, et al. 2007. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146: 406-415.
75. Solomon, D.H., M. Lunt & S. Schneeweiss. 2008. The risk of infection associated with tumor necrosis factor á antagonists. Arthritis Rheum. 58: 919-928.